Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00739986 · ClinicalTrials.gov registry record · Phase 2
Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
NCT00739986 is a Phase 2 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 152 participants.
The verdict
NCT00739986, a Phase 2 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
Study Summary
Assessment of the number of days' treatment with semapimod necessary for efficacy, as measured by response rate to CNI-1493 as compared to placebo, in patients with moderate to severe Crohn's disease (CD).
Interventions
- DRUG Placebo
- DRUG Semapimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2002-10 |
| Est. Completion | 2004-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00739986
The ClinicalTrials.gov registry entry for NCT00739986 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00739986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00739986 about?
NCT00739986 is a clinical study titled "Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo". Assessment of the number of days' treatment with semapimod necessary for efficacy, as measured by response rate to CNI-1493 as compared to placebo, in patients with moderate to severe Crohn's disease (CD).
What is the current status of trial NCT00739986?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2002-10. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00739986?
The interventions under investigation include: Placebo (DRUG), Semapimod (DRUG).
Who is sponsoring clinical trial NCT00739986?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.